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Introduction
Aspergillus spp. is a genus of saprophytic fungi, 
which is widely distributed in nature. This genus plays 
an important role in environmental nitrogen and car-
bon recycling and relies on conidia to spread in the air 
(Krüger et al. 2015; Latgé and Chamilos 2019). Among 
the approximately 200 Aspergillus species, less than 
20 are pathogenic for humans (Paulussen et al. 2017; 
Mead et al. 2019). Aspergillus fumigatus exerts a major 
influence on the number of pathogenic Aspergillus 
strains. Statistical data revealed that among multitudi-
nous Aspergillus spp. isolates, A. fumigatus accounted 
for 50–60%, A. flavus, A. terreus, and A. niger each 
made up 10–15% of the isolates, and other uncommon 
Aspergillus spp. were less than 2% (Paulussen et al. 2017; 
Hoenigl et al. 2018).
Of all pathogenic Aspergillus spp., A. fumigatus with 
airborne conidia is a prevailing agent for human infec-
tions. The small sizes of conidia allow them to reach 
the lung alveoli from the natural environment effort-
lessly. It is estimated that humans may inhale as many 
as hundreds of A. fumigatus conidia every day (Alanio 
et al. 2017; Takazono and Izumikawa 2018). In healthy 
hosts, the inhaled conidia are rapidly eliminated by 
a competent immune system composed of innate and 
adaptive immunity. The innate immunity plays pivotal 
role in destroying most of the inhaled conidia in the 
respiratory tract by respiratory ciliary movement and 
proteins on the surface of epithelial cells, and in recog-
nizing and engulfing the remaining conidia by alveolar 
phagocytes through surface pattern recognition recep-
tors. Simultaneously, phagocytes also induce inflam-
matory chemokines and cytokines and recruit other 
immune cells to destroy surviving A. fumigatus spores 
and hyphae. Among them, neutrophils can prevent the 
formation of hyphae and kill it; monocytes can phagocy-
tose spores to prevent fungal outbreaks. When dendritic 
cells phagocytose A. fumigatus, antigenic components 
are presented on the cell membrane surface to activate T 
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A b s t r a c t
Aspergillus fumigatus is one of the ubiquitous fungi with airborne conidia, which accounts for most aspergillosis cases. In immunocompetent 
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development against aspergillosis, particularly those based on AFMP4 protein, which might be a promising antigen for the development 
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K e y w o r d s: Aspergillus fumigatus, vaccine, Aspergillus fumigatus mannoprotein
Gu X. et al. 14
cells and B cells, initiating adaptive immunity of the 
body. Whereas, if the immune responses are excessively 
intensive, some immunological diseases such as allergic 
bronchopulmonary aspergillosis will occur. In immu-
nocompromised or immunodeficient hosts, such as the 
patients with immunosuppressive treatment for autoim-
mune disease, HIV suffers, and transplantation recipi-
ents, the growth of spores and hyphae of A. fumigatus 
cannot be prevented due to the decrease of neutrophils 
and phagocytes. Eventually, the hyphae of A. fumigatus 
will invade human blood vessels and spread from blood 
to the whole body, causing multi-system infection (Filler 
and Sheppard 2006). A. fumigatus is the most lethal 
invasive pathogenic fungus, with the mortality from 
invasive aspergillosis (IA) above 50%, even up to 95% 
(Dos Santos et al. 2020), especially for the patients with 
acute leukemia and hematopoietic stem cell transplanta-
tion (HSCT) (van de Peppel et al. 2018).
Despite the wide applications of antifungal drugs, 
they failed to provide satisfying treatment for invasive 
aspergillosis patients. Notably, the clear side effects of 
antifungal drugs such as amphotericin B’s kidney toxi-
city and the potential hepatotoxicity of itraconazole 
discouraged their clinical use. Although voriconazole 
had better penetration than amphotericin B and itra-
conazole, it might cause temporary hepatotoxicity. In 
addition to the side effects of antifungal drugs, drug 
resistance and high cost also greatly hindered the use 
of antifungal drugs. In response to the quest for more 
efficacious and safer therapeutic options, various new 
therapeutic drugs and new dosage forms of various 
therapeutic drugs are also in progress. The latest drugs, 
such as rifconazole and abaconazole, are being tested 
in various in vitro and in vivo trials (Jović et al. 2019). 
However, more studies still need to provide useful data 
on the efficacy and safety of new antifungal drugs. In 
consequence, the development of antifungal vaccines 
is highly proposed. Recently, A. fumigatus mannopro-
tein  4 (AFMP4) has been recognized as a  virulence 
factor of A. fumigatus and expected to serve as an anti-
gen for the development of anti-A. fumigatus vaccines. 
In this article, we systemically review the biological 
characters of Aspergillus spp. and the pathogenic and 
defense mechanisms of A. fumigatus to provide new 
strategies for the treatment of A. fumigatus.
Pathogenicity
Disease caused by A. fumigatus
A. fumigatus can cause a broad spectrum of aspergil-
losis ranging from mild to severe symptoms for immu-
nodeficient or immunosuppressed patients, including 
allergic syndromes, noninvasive infections, and IA 
(Bonnet et al. 2017; Pagano et al. 2017; Gamaletsou et al. 
2018; Xiao et al. 2020). The common diseases caused 
by A. fumigatus infection are as follows: (1) allergic 
bronchopulmonary aspergillosis (ABPA), (2) allergic 
sinusitis, (3) aspergilloma, (4) necrotizing pulmonary 
aspergillus (CNPA), (5) cutaneous aspergillosis, and 
(6) IA. In ABPA, the inflammation due to Aspergil­
lus infection of the lungs primarily affects the patients 
with asthma, cystic fibrosis, and bronchiectasis, which 
cause allergy symptoms such as fever, cough, wheeze, 
and generalized malaise. Allergic sinusitis is a nonin-
vasive and recurrent inflammatory sinusitis with the 
hypertrophic sinus and nasal polyps as the manifested 
symptoms in patients. Aspergilloma predominantly 
exhibits mycelial balls in the damaged lung bronchia, 
pulmonary cyst, or lung cavities, which causes a typi-
cal hemoptysis symptom in severe patients, and even 
threatens lives. CNPA usually occurs in patients with 
mild-to-moderate immunosuppression, accompanied 
with chronic symptoms like fever, cough, sputum, ano-
rexia, and weight loss with a duration of 1–6 months 
(Barac et al. 2017). Cutaneous aspergillosis is a cuta-
neous manifestation of disseminated Aspergillus infec-
tion, including erythematous-to-violaceous plaques or 
papules, commonly characterized by an ulcer or eschar 
(Sato and Tamai 2019). IA is a severe infection that 
significantly affects immunocompromised patients, 
such as those who have had an organ transplant or 
a  stem cell transplant operation. IA can affect each 
organ, but sinopulmonary diseases are the most com-
mon IA symptoms, including nasal congestion and 
pain, fever, pleuritic chest pain, and hemoptysis.
Molecular basis of A. fumigatus virulence
A. fumigatus is an opportunistic pathogen that causes 
~ 90% of IA with very high mortality (Darling and 
Milder 2018). Why A. fumigatus dominates the human 
pathogenicity is confusing to clinical medical work-
ers, which motivating scientists to explore its patho-
genic mechanisms. The pathogenicity of A. fumigatus 
to the host was mainly manifested by a direct attack 
with the pathogen’s virulent factors, the hypersensi-
tivity response of patients, or the innate and adaptive 
immunity of host evoked by virulent factors during 
the process of germinating in the host. In recent dec-
ades, especially after A. fumigatus AF293 strain genome 
sequencing in 2005, the virulence of A. fumigatus was 
shown to be multifactorial and was related to ther-
motolerance, cell wall composition and maintenance, 
resistance to immune response, toxins, nutrient uptake 
during invasive growth, signaling regulation, and aller-
gens (Darling and Milder 2018; Latgé and Chamilos 
2019). Besides, many molecules or genes related to 
the pathogenicity of A. fumigatus have been found, 
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including galactomannan glycoprotein encoded by 
afmp1, hydrophobic protein Rod A, fumagillin, glio-
toxin, helvolic acid, fumigaclavin C, asp-hemolysin, 
and so on. The genes and molecules associated with 
A. fumigatus virulence either were helpful for the sur-
vival of pathogens in the host, or contributed to the 
process of evading the immune system, such as masking 
the important PAMPs, inhibition of phagosome-lyso-
some fusion, production of antioxidants like catalase, 
SOD, and mannitol, or exerted multiple immunosup-
pressive actions on the host immunity by producing 
specific secondary metabolites such as gliotoxin (GT), 
fumagillin, actibind, and cytochalasin E.
The genes related to thermotolerance
As a  thermophilic fungus, A. fumigatus can grow 
at 55°C and survive at temperatures above 75°C. This 
ability facilitates to thrive in dead or decayed organic 
matters and to infect mammalian host cells. Thus, the 
genes related to thermotolerance contribute to the viru-
lence of A. fumigatus. Five genes have been proved to 
be associated with the thermotolerance of A. fumigatus 
(thtA, cgrA, afpmt1, kre2/afmnt1, and hsp1/asp f 12). 
The thtA gene is necessary for the growth of A. fumiga­
tus at 48°C, but it is not involved in the pathogenicity 
of A. fumigatus. The afpmt1 gene encodes for one man-
nosyl transferase, which is essential for the growth of 
A. fumigatus over 37°C. It was found that the ∆afmnt1 
mutant was attenuated in a mouse infection model and 
more sensitive to azoles (Wagener et al. 2008).
Toxins
A. fumigatus produce toxins for protection against 
predators and competitors, and they can directly attack 
the host and contribute to the pathogenesis of the fun-
gus. Many toxins are secondary metabolites of fungi. 
They can affect the synthesis of DNA, RNA, and pro-
teins, or alter cell membrane and impair cellular func-
tions. Many toxins and relevant genes of A. fumigatus 
have been studied, such as diffusible toxic substances 
from conidia, gliotoxin (gliP and gliZ), mitogillin (res/
mitF/aspf1), hemolysin (aspHS), verruculogen, fuma-
gillin, and the transcription factor laeA. Gliotoxin is 
the most potent toxin produced by A. fumigatus (Zhang 
et al. 2019), which can suppress macrophage phagocy-
tosis, T cell proliferation, cytotoxic T cell response, and 
monocyte apoptosis (Schlam et al. 2016; Schmidt et al. 
2017; Fraga-Silva et al. 2019). Gliotoxin can also inhibit 
the NADPH of neutrophils (Tsunawaki et al. 2004), 
suppress ROS production, and impair the neutrophil’s 
phagocytic capacity (Orciuolo et al. 2007). In addition, 
it should be noted that the transcription factor laeA 
is a crucial regulator for secondary metabolite biosyn- 
thesis (Pfannenstiel et al. 2017), and it has been proved 
that laeA deletion in A. fumigatus inhibited the pro-
duction of almost all secondary metabolites containing 
gliotoxin (Arias et al. 2018).
Allergens
 Moreover, A. fumigatus can produce a large number 
of allergens; among them 23 have their official names 
ranging from Asp f1 to Asp f34 (available at: http://
www.allergen.org/, updated on July  11, 2019). Some 
allergens show toxic or enzymatic activities, which are 
related to the virulence. Other allergenic molecules 
have no virulence functions. All Aspergillus allergens 
are likely to trigger a Type I hypersensitivity response in 
patients and induce a high-affinity IgE antibody produc-
tion. Aspergillus allergens can cause hypersensitivities 
in immunocompetent patients, such as ABPA, allergic 
rhinosinusitis, asthma, and aspergilloma. In immuno-
compromised patients, these aller genic molecules can 
significantly increase the risk of aspergillosis. Many 
Aspergillus allergens have been explored and developed 
for diagnostic purposes (Masaki et al. 2017).
Other pathogenic factors
So far, none of the pathogenic factors is unique to 
A. fumigatus, and it is necessary to further investigate 
why A. fumigatus is more pathogenic than other com-
mon conditional pathogens. Some scholars believed 
that, unlike other human pathogenic bacteria such 
as Candida and Cryptococcus, the pathogenicity of 
A. fumigatus is not caused by one or several pathogenic 
factors but caused by the result of its unique biological 
characteristics such as growth and metabolism and the 
joint action of multiple pathogenic factors.
Recently, based on the homology between fungal 
endoether glucokinase and AnmK kinase of bacte-
rial cell wall circulatory metabolism, we proposed the 
hypothesis that fungal cell wall has a mechanism simi-
lar to that of bacterial cell wall circulatory metabolism, 
which plays a role in the growth and reproduction of 
fungi. Whether this hypothesis is correct and related 
to the pathogenicity of A. fumigatus needs to be further 
confirmed by research.
Defense mechanism against A. Fumigatus
Host immunity to A. fumigatus
Innate defense immunity
Anatomical barriers. At the entry point of airborne 
conidia, the upper respiratory tract’s airway epithelium 
is the first defensive line of innate host immunity against 
A. fumigatus. As an airway epithelium cell, the mucous 
secreting cell can secrete mucus to trap inhaled conidia. 
Another airway epithelium cell, a ciliated cell, can 
drive the trapped conidia to the oropharyngeal junction 
Gu X. et al. 16
(van de Veerdonk et al. 2017). In this way, a significant 
number of A. fumigatus are expulsed from the lung. The 
respiratory epithelium can also secrete some peptides 
or enzymes to combat A. fumigatus, indicating that chi-
tinase produced by epithelium can damage chitin on the 
cell wall of A. fumigatus (Garth et al. 2018).
Professional phagocytes and classical signaling path­
ways. The dominant role of phagocytes defense against 
A. fumigatus in vivo and in vitro has been reported (Liu 
et al. 2017; Almeida et al. 2019; Mackel and Steele 2019). 
The primary phagocytes responsible for the phagocy-
tosis of A. fumigatus are alveolar macrophages (AM) 
and neutrophils.
In the lung of the immunocompetent host, certain 
soluble recognition receptors produced by alveolar 
macrophages such as Pentraxin 3 (PTX3) and surface 
protein-D (SP-D) can immediately bind to the inhaled 
conidia of A. fumigatus, and enhance the phagocytosis 
of alveolar macrophages (Smole et al. 2020). Alveolar 
macrophages then recognize and swallow the conidia 
through the TLR2/4 and Dectin-1. Toll-like receptors 
(TLRs) are type I membrane receptors that function in 
recognition of PAMPs and an intracellular TLR domain 
required for downstream signaling. TLRs can recog-
nize pathogens and activate transcription factors such 
as NF-κB, which mediate the expression of inflamma-
tory cytokines and chemokines (Anthoney et al. 2018). 
Some studies implicated the membrane receptors TLR2 
and TLR4 were the crucial recognition components for 
host defense against A. fumigatus (Dai et al. 2019). An 
essential role for TLR2 and TLR4 in cytokine produc-
tion against A. fumigatus has been established in many 
in vitro studies (Briard et al. 2019; Gupta et al. 2019). 
Dectin-1 is a type II transmembrane protein, which 
is highly expressed in macrophages, neutrophils, and 
DCs. Dectin-1 can recognize β-glucan on germinating 
conidian but cannot identify the resting conidia, allow-
ing macrophages to differentiate the various forms of 
A. fumigatus (Li et al. 2019; Dutta et al. 2020). Alveolar 
macrophages capture conidia leading to a proinflam-
matory response accompanied by the secretion of 
many cytokines and chemokines, including TNF-α and 
CXCL2 (Chemokine (C-X-C motif) ligand 2), which 
are essential activators for neutrophil recruitment (Guo 
et al. 2020). The conidia escaped from the phagocyto-
sis by alveolar macrophages continue to germinate and 
spread. Proinflammatory factors derived by alveolar 
macrophages and epithelial cells recruit neutrophils 
to the infection site. Neutrophils perform an effective 
elimination of the germinating conidia and hyphae.
In the immunocompetent lung, conidia are imme-
diately trapped by the soluble recognition receptors 
(PTX3, SP-D), promoting conidial phagocytosis by 
alveolar macrophage (AM). AM also captures conidia 
through TLRs and Dectin-1, leading to a proinflam-
matory response. The escaped conidia continue to 
germinate and penetrate through the alveolar epithe-
lial cells. Neutrophils employ the processes of NET for-
mation, degranulation, and lactoferrin production to 
inactivate germinating conidia and hyphae. Dendritic 
cells phagocytose, and process germinated conidia 
for antigens presentation to T cells, and finally activate 
an adaptive immune response to A. fumigatus (Garth 
and Steele 2017).
Mechanism of innate immune cells removing A. fumi­
gatus. The mechanism includes phagocytosis, reactive 
oxygen species (ROS) generations mediated by nico-
tinamide adenine dinucleotide phosphate-oxidase 
(NADPH), lactoferrin production, and neutrophil 
extracellular traps (NETs) formation (Schoen et al. 
2019; Souza et al. 2019; Shopova et al. 2020). ROS pro-
duction responds to swollen conidia, but not resting 
conidia, through NADPH oxidase activation (Ferling 
et al. 2020; Khani et al. 2020). It has been demonstrated 
that the ROS-producing complex plays a crucial fun-
gicidal role during A. fumigatus infection (Shen et al. 
2016). NETs are networks of extracellular fibers, mainly 
composed of DNA from neutrophils. The NET forma-
tion is induced by a variety of proinflammatory media-
tors such as IL-8. It is significant for defense against 
large pathogens, such as hyphae of A. fumigatus (Li et al. 
2020). It has been demonstrated both in vitro and in 
vivo, NET formation is dependent on NADPH oxidase 
and ROS generation (Khan et al. 2019; Ravindran et al. 
2019). In addition, dendritic cells (DCs) play a well-
established role in the host defense against A. fumigatus. 
Immature DCs can phagocytose conidia and hyphae 
through PRRs and present the processed antigens of 
A. fumigatus to host T cells, leading to the activation 
of adaptive immune responses (Wang et al. 2017).
Adaptive immunity mechanism
The elimination of the daily-inhaled conidia mainly 
depends on the innate immune response, but the treat-
ment for serious Aspergillus infections relies on the 
cooperation of the adaptive immune system, which 
responds to the signaling generated by innate immu-
nity. Lymphocytes T and B represent the two main parts 
of the adaptive defensive system.
Role of T cells in adaptive immunity. The T cell immu-
nity system interacts with the innate immune response 
in many ways. For instance, DCs recruit at the infec-
tion sites can load and migrate the A. fumigatus antigen 
to lymph nodes, leading to T lymphocytes’ activation 
(Wang et al. 2017). CD4+ T cells are the dominating 
organizer, which play a major role in antifungal immu-
nity. These activated T cells are able to invoke phago-
cytes or restrict the immune response. The initiating 
of CD4+ T cell immunity occurred between TCR and 
its cognate antigens on the DC cells. The excessive 
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inflammatory response secreted by the activated  T 
cells can induce the naïve T cells to differentiate into 
CD4 T help (Th) subsets while damaging the incident 
tissues and contributing to the invasive infections of 
A. fumigatus. Th1 response was the predominant cell 
type that involved the protective immune response to 
the host through the production of pro-inflammatory 
cytokines such as IFN-γ, IL-2, IL-12, and TNF-α. 
In contrast, Th2 immune response was associated with 
the germination of fungal and exacerbation of disease 
as well as induced the alternatively activated macro-
phages in the defense against A. fumigatus. The balance 
between Th1 and Th2 subset determined the quality and 
outcome of host immune responses. It was also found 
that Th17 played multiple roles in clearing infections 
by participating in the production of proinflammatory 
genes and anti microbial peptides, recruitment, and acti-
vation of neutrophils (Pathakumari et al. 2020). T cell 
immunity against fungal infections primes Th1  type 
response (Shenoy et al. 2017). However, in patients with 
aspergillosis, the predominance of Th2 T cells’ immune 
response was conducted to exacerbate disease (Dewi 
et al. 2017). Besides, DCs contribute to a  damaging 
inflammatory response by stimulating the Th17 cells 
and producing IL-23 (Movahed et al. 2018).
Humoral immunity to A. fumigatus. The function 
of Aspergillus-specific antibodies in immunocompro-
mised patients with IA has been investigated (Boniche 
et al. 2020). Early researches indicated that the anti-
body responses failed to provide effective protection 
against IA or played only a minor role in fighting asper-
gillosis (Cutler et al. 2007). However, recent research 
reported that β-1,3-glucan specific antibodies could 
not only inhibit Aspergillus hyphae but also protect 
CD2F1 mice against Aspergillus challenge (Matveev 
et al. 2019). Although it is generally acknowledged that 
T cells immunity plays a vital role in combating fungal 
aspergillosis (Diaz-Arevalo and Kalkum 2017), there 
are a variety of ways, such as opsonization, comple-
ment activation, and virulence factors neutralization, 
in which antibodies affect T cells response and sup-
press the growth, adherence, and germination of fungi 
(Liedke et al. 2017; Ulrich and Ebel 2020).
Progress of anti-A. fumigatus vaccines development
Despite the wide applications of antifungal drugs, 
they failed to provide satisfying treatment for IA 
patients. The therapy with antifungal drugs is often 
associated with side effects, drug-resistance, and high 
costs. To overcome these disadvantages, the develop-
ment of alternative methods, including antifungal vac-
cines, is highly desirable. Antifungal vaccine studies’ 
primary tool is the employment of fungal particulate 
forms, homogenates, or recombinant proteins. Some 
studies revealed that the immunization with conidia, 
mycelia extracts, or fungal culture filtrates induced 
effective protection against Aspergillus infections 
(Muthu et al. 2018; Pérez-Cantero et al. 2019). The heat-
killed mutant strain was also reported to be a broad-
spectrum fungal vaccine that induced host protection 
against common invasive fungal infections in both 
immunocompetent and immunocompromised hosts 
(Wang et al. 2019). However, the crude extracts com-
monly consist of abundant fungal components as vari-
ous carbohydrates, nucleic acids, or even some toxins 
(Shishodia et al. 2019). Thus, vaccination using purified 
recombinant antigenic protein or peptide-based vac-
cine (Da Silva et al. 2020) is a more popular method 
in antifungal vaccine studies, whereas the possibility 
of potential severe anaphylaxis remains.
Obstacles in vaccine development
Although recently there is some progress published 
on the study of vaccines against A. fumigatus (Chau-
vin et al. 2019; Khani et al. 2020), several significant 
obstacles remain to be overcome for producing effec-
tive vaccine (Levitz 2017). First of all, since A. fumigatus 
is an opportunistic pathogen and most invasive infec-
tions appear in the immunocompromised population, 
the induction of an effective adaptive immunity in 
such individuals is a real challenge. One of the feasible 
measures is the prophylactic vaccination, especially in 
target population, such as the patients waiting for bone 
marrow transplant and the patients before the treat-
ment with immunosuppressive agents. Another major 
problem in developing a vaccine against A. fumigatus is 
related to the fungus’ molecular complexity. The extract 
of A. fumigatus is a mixture containing up to 200 dif-
ferent proteins, glycoproteins, and compounds of low 
molecular weights. In addition, safety issues should also 
be well addressed because a wide range of allergic dis-
eases correlates with Aspergillus allergens. The poten-
tial of activating an adverse immunoreaction is also an 
intractable problem (Dewi et al. 2017).
Adaptive immunity induced
by anti-A. fumigatus  vaccines
Currently, some A. fumigatus allergens were identi-
fied based on their reactivity to patients’ antibodies. 
Some of these allergens are not effective antigens for 
vaccine development because they primarily induce Th2 
cell response but cannot provide adequate protection 
against Aspergillus infection. Nevertheless, a recombi-
nant allergen of A. fumigatus – Aspf3 was confirmed to 
induce protective response when presented mixed with 
TM adjuvant in a murine inhalation model (Namvar 
et al. 2015). It was also reported that various yeast gen-
era could activate innate CD8+ T lymphocyte response 
and generate broad antifungal protection (Bazan et al. 
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2018). It suggested yeasts as a potential antifungal vac-
cine candidate to activate antigen-specific CD8+ T cell 
responses effectively.
For a long time, most antifungal vaccine research 
intended to activate memory T lymphocytes and raise 
a Th1 type immune response that would produce some 
favorable cytokines to enhance phagocytosis or T cell 
killing (Upadhya et al. 2016). Most studies suggested 
that the protective antifungal reactions induced by vac-
cines are cell-mediated immune responses. However, 
some recent investigations focused on protective anti-
bodies. One β-glucan conjugate vaccine was shown to 
provide good protection against Candida albicans and 
A. fumigatus (Catellani et al. 2020). The serum of vac-
cinated mice significantly inhibited the growth of fun-
gus hyphae. The mechanism of the β-glucan conjugate 
vaccine might involve specific anti-β-glucan antibody 
(Matveev et al. 2019).
Optimizing vaccination schedules
with A. fumigatus mannoprotein (AFMP)
The cell wall of fungi is primarily defensive to a hos-
tile environment (Ruiz-Herrera and Ortiz-Castellanos 
2019). Except for physical protection, one central role 
of the fungus cell wall is the interaction with the hosts. 
Therefore, the cell wall components are usually the tar-
gets to be attacked by the immune cells in hosts. The 
cell wall of A. fumigatus is mainly composed of poly-
saccharides and proteins. The polysaccharides con-
sist of glucan, mannose, and chitin, which constitute 
a three-dimensional network. β-(1,3)-glucan branched 
with β-(1,6)-glucan forms the wall’s skeleton. Chitin, 
a polymer of N-acetylglucosamine is covalently linked 
to β-glucan. Several proteins of the cell wall are man-
nosylated. The role of some mannoprotein has been 
investigated and suggested as antigenic determinants 
for serodiagnosis.
Mannoproteins (MPs) are natural glycoconjugates 
expressed mainly on the fungal surface and released 
into the culture medium during fungal growth. MPs 
have been implicated as important antigens involved 
in the induction of T cell-mediated immunity (Schülke 
2018; Paulovičová et al. 2019). Therefore, MP may have 
potential use as an immunomodulator in patients at 
high risk of IA.
The afmp genes were reported to encode some cell 
wall MPs of A. fumigatus. Among them, afmp1 encodes 
a protein-AFMP1 with 284 amino acids, which con-
tains some similar sequences present in MP of Peni­
cillium marneffei (Muszewska et al. 2017). AFMP2 
also includes a few domains of MP1 (Woo et al. 2018). 
Remarkably, specific AFMP1 and AFMP2 antibodies 
were found in the aspergillosis or aspergilloma patients 
during A. fumigatus infections (Woo et al. 2018). More-
over, recombinant AFMP1 protein was also applied in 
the ELISA assay to detect specific AFMP1 antibodies in 
hosts, which greatly contributes to the rapid diagnosis 
of A. fumigatus-related aspergillosis (Woo et al. 2018). 
Based on this research, another two A. fumigatus MPs, 
AFMP3, and AFMP4 proteins were discovered during 
BLASTP searching conserved sequence domains of 
AFMP2 (Woo et al. 2018). Furthermore, it was dem-
onstrated that AFMP1 and AFMP4 monoclonal anti-
bodies had been generated and used to develop two 
ELISA methods to detect AFMP1 and AFMP4. These 
antigen-capture ELISA methods can rapidly and spe-
cifically detect AFMP1 or AFMP4 in the cultures of 
A. fumigatus without the cross-reactivity with other 
pathogenic Aspergillus species (Woo et al. 2018).
In MP1 and AFMP1~AFMP4 proteins, there is 
a putative signal peptide at the N-terminal site, which 
instructs secretory proteins to the endoplasmic reticu-
lum route (Woo et al. 2018), as well as several homolo-
gous conserved domains detected through phyloge-
netic analysis. Considering that the virulence role of 
Penicillium marneffei mannoprotein 1 (MP1) has been 
confirmed (Woo et al. 2018), AFMPs may contribute 
to the virulence of A. fumigatus likewise. Our collabo-
rators compared the difference in virulence between 
wild A. fumigatus and various afmp mutants (Woo 
et al. 2018). The results showed that among the four 
afmp1-afmp4 single knockdown mutants, the virulence 
of A. fumigatus distinctly decreased only in the afmp4 
mutant. The mice infected by the conidia of afmp1-
afmp3 single knockdown strains did not distinguish the 
survival rates in the mice challenged with conidia of 
wild type A. fumigatus. It implied that afmp1, afmp2, 
afmp3 might not be the crucial toxic factors, whereas 
afmp4 is very likely to be a decisive virulence factor for 
A. fumigatus and may be used as a promising antigen 
for the development of vaccines against A. fumigatus.
Conclusions
The multifactorial virulence factors and complex 
pathogenic mechanism of A. fumigatus put forward 
higher requirements for the prevention and control of 
fungal. Advances in the understanding of pathogenicity 
and host immune response to A. fumigatus would be 
conductive to propose new strategies for antifungal vac-
cines. The AFMP4 protein of A. fumigatus, which has 
been identified at the molecular levels, might serve as 
a promising candidate antigen for developing vaccines 
against invasive aspergillosis. Alternatively, a pan-fun-
gal vaccine with a broader antifungal spectrum derived 
from the conserved fungal cell surface epitopes might 
be the most promising antifungal vaccine in the future. 
Also, several studies of animal models, adjuvants, and 
Aspergillus fumigatus vaccine1 9
immunomodulators would provide novel strategies for 
the design of antifungal vaccines. Nevertheless, with 
antifungal vaccines’ progress, these vaccines’ efficacy 
and efficiency need to be improved.
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